[Risk-adapted therapy of acute myeloid leukemia].
Genetic and molecular techniques have provided increasing insights into the biology of acute myeloid leukemia (AML). These investigations showed that AML is not a homogeneous disease but a heterogeneous group of biologically different subentities. These subentities are currently primarily defined by cytogenetics and molecular markers. They differ substantially in response to therapy and long-term outcome and hence allow different risk groups of patients to be defined. These will guide therapeutic decisions in future therapeutic strategies and may ultimately lead to an individualized treatment concept.
Hiddemann
W
W
Medizinische Klinik III, Universität München, Grosshadern, 81377 München. sekrmed3@med3.med.uni-muenchen.de
Spiekermann
K
K
Braess
J
J
Feuring-Buske
M
M
Buske
C
C
Büchner
T
T
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000145:classification*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors
D000970:Antineoplastic Agents